Magenta Therapeutics (MGTA) is disclosing preliminary clinical trial results on Thursday on an experimental therapy designed to expand the number of beneficial stem cells contained in stored umbilical cord blood. These early data, culled from a handful of patients, are mixed.
The Magenta therapy, called MGTA-456, improved the performance of stem cell transplants. But there were also worrisome signs of an autoimmune reaction in some patients. As a result, the biotech is altering its clinical development plan.
About the Author Reprints
